LP
CNCE

LMR Partners’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

LMR Partners’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-15,752
Closed -$66K – 1268
2021
Q2 		$66K Buy
+15,752
New +$66.7K ﹤0.01% 946
2014
Q3 		– Sell
-14,394
Closed -$146K – 505
2014
Q2 		$146K Buy
+14,394
New +$139K 0.01% 423

Other funds holding CNCE

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

LMR Partners's CNCE Position: Q3 2021 in Review

LMR Partners sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q3 2021, closing a stake of 15,752 shares — an estimated $66K sold.

LMR Partners first reported a position in CNCE in Q2 2014 and held it in 2 quarters. The position peaked at $146K in Q2 2014. 61 funds tracked by Wall St. Rank hold CNCE as of Q3 2021.

  • LMR Partners reported no remaining Concert Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
  • LMR Partners sold 15,752 Concert Pharmaceuticals, Inc. shares in Q3 2021, an estimated $66K.
  • LMR Partners first reported a position in Concert Pharmaceuticals, Inc. in Q2 2014 and held it in 2 quarters.
  • LMR Partners's Concert Pharmaceuticals, Inc. position peaked at $146K in Q2 2014.
  • 61 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q3 2021.

Based on LMR Partners's 13F filing for Q3 2021, filed 15 Nov 2021.